FOXO1 increases CCL20 to promote NF-κB-dependent lymphocyte chemotaxis

Molecular Endocrinology

Volumn 26, Issue 3, 2012, Pages 423-437

  Miao, Hongming ^a   Zhang, Yang ^a   Lu, Zhongyan ^a   Yu, Liqing ^b   Gan, Lixia ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORKHEAD BOX CONTAINING PROTEIN O SUBFAMILY 1; FORKHEAD TRANSCRIPTION FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; PROTEIN P50; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL MIGRATION; CELL SECRETION; CELL STRAIN HEPG2; CHEMOTAXIS; CYTOKINE PRODUCTION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INSULIN RESISTANCE; LYMPHOCYTE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; TRANSCRIPTION INITIATION;

ANIMALS; BASE SEQUENCE; CHEMOKINE CCL20; CHEMOTAXIS; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HEP G2 CELLS; HUMANS; INFLAMMATION; INSULIN; LIVER; LYMPHOCYTES; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; NF-KAPPA B P50 SUBUNIT; PROTEIN BINDING; RESPONSE ELEMENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; MUS;

EID: 84863165430     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2011-1233     Document Type: Article

References (60)

1. Browning JD, Horton JD 2004 Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114:147-152.
2. Guo S, Rena G, Cichy S, He X, Cohen P, Unterman T 1999 Phos- phorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence. J Biol Chem 274:17184-17192.
3. Rena G, Guo S, Cichy SC, Unterman TG, Cohen P 1999 Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J Biol Chem 274:17179-17183.
4. del Peso L, González VM, Hernández R, Barr FG, Núñez G 1999 Regulation of the forkhead transcription factor FKHR, but not the PAX3-FKHR fusion protein, by the serine/threonine kinase Akt. Oncogene 18:7328-7333.
5. Nakae J, Kitamura T, Silver DL, Accili D 2001 The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose- 6-phosphatase expression. J Clin Invest 108:1359-1367.
6. Barthel A, Schmoll D, Krüger KD, Bahrenberg G, Walther R, Roth RA, Joost HG 2001 Differential regulation of endogenous glucose- 6-phosphatase and phosphoenolpyruvate carboxykinase gene expression by the forkhead transcription factor FKHR in H4IIE-hepatoma cells. Biochem Biophys Res Commun 285:897-902.
7. Kodama S, Koike C, Negishi M, Yamamoto Y 2004 Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes. Mol Cell Biol 24:7931-7940.
8. Kamagate A, Qu S, Perdomo G, Su D, Kim DH, Slusher S, Meseck M, Dong HH 2008 FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest 118:2347-2364.
9. Sparks JD, Dong HH 2009 FoxO1 and hepatic lipid metabolism. Curr Opin Lipidol 20:217-226.
10. de Candia P, Blekhman R, Chabot AE, Oshlack A, Gilad Y 2008 A combination of genomic approaches reveals the role of FOXO1a in regulating an oxidative stress response pathway. PLoS One 3:e1670.
11. Kumashiro N, Tamura Y, Uchida T, Ogihara T, Fujitani Y, Hirose T, Mochizuki H, Kawamori R, WatadaH2008 Impact of oxidative stress and peroxisome proliferator-activated receptor γ coactivator- α1in hepatic insulin resistance. Diabetes 57:2083-2091.
12. Park SJ, Sohn HY, Yoon J, Park SI 2009 Down-regulation of FoxOdependent c-FLIP expression mediates TRAIL-induced apoptosis in activated hepatic stellate cells. Cell Signal 21:1495-1503.
13. Su D, Coudriet GM, Hyun Kim D, Lu Y, Perdomo G, Qu S, Slusher S, Tse HM, Piganelli J, Giannoukakis N, Zhang J, Dong HH 2009 FoxO1 links insulin resistance to proinflammatory cytokine IL-1β production in macrophages. Diabetes 58:2624-2633.
14. Ito Y, Daitoku H, Fukamizu A 2009 Foxo1 increases pro-inflammatory gene expression by inducing C/EBP β in TNF-α-treated adipocytes. Biochem Biophys Res Commun 378:290-295.
15. Samuel VT, Choi CS, Phillips TG, Romanelli AJ, Geisler JG, Bhanot S, McKay R, Monia B, Shutter JR, Lindberg RA, Shulman GI, Veniant MM 2006 Targeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. Diabetes 55:2042-2050.
16. Valenti L, Rametta R, Dongiovanni P, Maggioni M, Fracanzani AL, Zappa M, Lattuada E, Roviaro G, Fargion S 2008 Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis. Diabetes 57:1355-1362.
17. Charo IF, Ransohoff RM 2006 The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354:610-621.
18. Oo YH, Shetty S, Adams DH 2010 The role of chemokines in the recruitment of lymphocytes to the liver. Dig Dis 28:31-44.
19. Rot A, von Andrian UH 2004 Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 22:891-928.
20. Schaerli P, Moser B 2005 Chemokines: control of primary and memory T-cell traffic. Immunol Res 31:57-74.
21. Berres ML, Nellen A, Wasmuth HE 2010 Chemokines as immune mediators of liver diseases related to the metabolic syndrome. Dig Dis 28:192-196.
22. Bertola A, Bonnafous S, Anty R, Patouraux S, Saint-Paul MC, Iannelli A, Gugenheim J, Barr J, Mato JM, Le Marchand-Brustel Y, Tran A, Gual P 2010 Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS One 5:e13577.
23. Hieshima K, Imai T, Opdenakker G, Van Damme J, Kusuda J, Tei H, Sakaki Y, Takatsuki K, Miura R, Yoshie O, Nomiyama H 1997 Molecular cloning of a novel human CC chemokine liver and activation- regulated chemokine (LARC) expressed in liver. Chemotactic activity for lymphocytes and gene localization on chromosome 2. J Biol Chem 272:5846-5853.
24. Rossi DL, Vicari AP, Franz-Bacon K, McClanahan TK, Zlotnik A 1997 Identification through bioinformatics of two new macrophage proinflammatory human chemokines: MIP-3α and MIP-3β. J Immunol 158:1033-1036.
25. Hromas R, Gray PW, Chantry D, Godiska R, Krathwohl M, Fife K, Bell GI, Takeda J, Aronica S, Gordon M, Cooper S, Broxmeyer HE, Klemsz MJ 1997 Cloning and characterization of exodus, a novel β-chemokine. Blood 89:3315-3322.
26. Schutyser E, Struyf S, Van Damme J 2003 The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev 14: 409-426.
27. Yamashiro S, Wang JM, Yang D, Gong WH, Kamohara H, Yoshimura T 2000 Expression of CCR6 and CD83 by cytokine-activated human neutrophils. Blood 96:3958-3963.
28. Harant H, Eldershaw SA, Lindley IJ 2001 Human macrophage inflammatory protein-3α/CCL20/LARC/Exodus/SCYA20 is transcriptionally upregulated by tumor necrosis factor-α via a nonstandard NF-κB site. FEBS Lett 509:439-445.
29. Duffaut C, Zakaroff-Girard A, Bourlier V, Decaunes P, Maumus M, Chiotasso P, Sengene's C, Lafontan M, Galitzky J, Bouloumié A 2009 Interplay between human adipocytes and T lymphocytes in obesity: CCL20 as an adipochemokine and T lymphocytes as lipogenic modulators. Arterioscler Thromb Vasc Biol 29:1608-1614.
30. Hirata T, Osuga Y, Takamura M, Kodama A, Hirota Y, Koga K, Yoshino O, Harada M, Takemura Y, Yano T, Taketani Y 2010 Recruitment of CCR6-expressing Th17 cells by CCL 20 secreted from IL-1 β-, TNF-α-, and IL-17A-stimulated endometriotic stromal cells. Endocrinology 151:5468-5476.
31. Shimizu Y, Murata H, Kashii Y, Hirano K, Kunitani H, Higuchi K, Watanabe A 2001 CC-chemokine receptor 6 and its ligand macrophage inflammatory protein 3α might be involved in the amplification of local necroinflammatory response in the liver. Hepatology 34:311-319.
32. Fujiie S, Hieshima K, Izawa D, Nakayama T, Fujisawa R, Ohyanagi H, Yoshie O 2001 Proinflammatory cytokines induce liver and activation-regulated chemokine/macrophage inflammatory protein- 3α/CCL20 in mucosal epithelial cells through NF-κB [correction of NK-kappaB]. Int Immunol 13:1255-1263.
33. Nakayama T, Fujisawa R, Yamada H, Horikawa T, Kawasaki H, Hieshima K, Izawa D, Fujiie S, Tezuka T, Yoshie O 2001 Inducible expression of a CC chemokine liver- and activation-regulated chemokine (LARC)/macrophage inflammatory protein (MIP)-3 α/CCL20 by epidermal keratinocytes and its role in atopic dermatitis. Int Immunol 13:95-103.
34. Nguyen H, Sankaran S, Dandekar S 2006 Hepatitis C virus core protein induces expression of genes regulating immune evasion and anti-apoptosis in hepatocytes. Virology 354:58-68.
35. Yang J, Goldstein JL, Hammer RE, Moon YA, Brown MS, Horton JD 2001 Decreased lipid synthesis in livers of mice with disrupted Site-1 protease gene. Proc Natl Acad Sci USA 98:13607-13612.
36. Alikhani M, Alikhani Z, Graves DT 2005 FOXO1 functions as a master switch that regulates gene expression necessary for tumor necrosis factor-induced fibroblast apoptosis. J Biol Chem 280: 12096-12102.
37. Baba M, Imai T, Nishimura M, Kakizaki M, Takagi S, Hieshima K, Nomiyama H, Yoshie O 1997 Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARC. J Biol Chem 272:14893-14898.
38. Durham SK, Suwanichkul A, Scheimann AO, Yee D, Jackson JG, Barr FG, PowellDR1999 FKHR binds the insulin response element in the insulin-like growth factor binding protein-1 promoter. Endocrinology 140:3140-3146.
39. Kwon JH, Keates S, Simeonidis S, Grall F, Libermann TA, Keates AC 2003 ESE-1, an enterocyte-specific Ets transcription factor, regulates MIP-3α gene expression in Caco-2 human colonic epithelial cells. J Biol Chem 278:875-884.
40. Lorenzo M, Fernández-Veledo S, Vila-Bedmar R, Garcia-Guerra L, De Alvaro C, Nieto-Vazquez I 2008 Insulin resistance induced by tumor necrosis factor-α in myocytes and brown adipocytes. J Anim Sci 86:E94-E104.
41. Guo S, Dunn SL, White MF 2006 The reciprocal stability of FOXO1 and IRS2 creates a regulatory circuit that controls insulin signaling. Mol Endocrinol 20:3389-3399.
42. Matsuzaki H, Daitoku H, Hatta M, Tanaka K, Fukamizu A 2003 Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc Natl Acad Sci USA 100:11285-11290.
43. Altomonte J, Cong L, Harbaran S, Richter A, Xu J, Meseck M, Dong HH 2004 Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest 114:1493-1503.
44. Cheng Z, Guo S, Copps K, Dong X, Kollipara R, Rodgers JT, Depinho RA, Puigserver P, White MF 2009 Foxo1 integrates insulin signaling with mitochondrial function in the liver. Nat Med 15:1307-1311.
45. Tilg H, Moschen AR 2008 Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 19:371-379.
46. Sugita S, Kohno T, Yamamoto K, Imaizumi Y, Nakajima H, Ishimaru T, Matsuyama T 2002 Induction of macrophage-inflammatory protein-3α gene expression by TNF-dependent NF-κB activation. J Immunol 168:5621-5628.
47. Fan W, Yanase T, Morinaga H, Okabe T, Nomura M, Daitoku H, Fukamizu A, Kato S, Takayanagi R, Nawata H 2007 Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. J Biol Chem 282:7329-7338.
48. Gregor MF, Hotamisligil GS 2011 Inflammatory mechanisms in obesity. Annu Rev Immunol 29:415-445.
49. Fan W, Morinaga H, Kim JJ, Bae E, Spann NJ, Heinz S, Glass CK, Olefsky JM 2010 FoxO1 regulates Tlr4 inflammatory pathway signalling in macrophages. EMBO J 29:4223-4236.
50. Kortylewski M, Feld F, Krüger KD, Bahrenberg G, Roth RA, Joost HG, Heinrich PC, Behrmann I, Barthel A 2003 Akt modulates STAT3-mediated gene expression through a FKHR (FOXO1a)-dependent mechanism. J Biol Chem 278:5242-5249.
51. Lawrence T 2009 The nuclear factor NF-κB pathway in inflammation. Cold Spring Harb Perspect Biol 1:a001651.
52. Shoelson SE, Lee J, Goldfine AB 2006 Inflammation and insulin resistance. J Clin Invest 116:1793-1801.
53. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE 2005 Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat Med 11:183-190.
54. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C 2008 Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 14:72-81.
55. Rivera CA 2008 Risk factors and mechanisms of non-alcoholic steatohepatitis. Pathophysiology 15:109-114.
56. Syn WK, Choi SS, Diehl AM 2009 Apoptosis and cytokines in non-alcoholic steatohepatitis. Clin Liver Dis 13:565-580.
57. Tilg H, Moschen AR 2010 Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52:1836-1846.
58. Beraza N, Malato Y, Vander Borght S, Liedtke C, Wasmuth HE, Dreano M, de Vos R, Roskams T, Trautwein C 2008 Pharmacological IKK2 inhibition blocks liver steatosis and initiation of nonalcoholic steatohepatitis. Gut 57:655-663.
59. Mas E, Danjoux M, Garcia V, Carpentier S, Ségui B, Levade T. 2009 IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis. PLoS One 4:e7929.
60. Lewis JR, Mohanty SR 2010 Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 55:560-578